Myovant Sciences (NYSE:MYOV) posted its quarterly earnings data on Tuesday. The company reported ($0.89) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.95) by $0.06, Bloomberg Earnings reports.
Shares of MYOV stock traded up $0.34 on Wednesday, reaching $7.29. The company had a trading volume of 26,189 shares, compared to its average volume of 271,536. The firm has a market capitalization of $622.86 million, a PE ratio of -1.78 and a beta of 1.05. The company has a debt-to-equity ratio of 21.51, a current ratio of 2.32 and a quick ratio of 2.32. Myovant Sciences has a one year low of $6.60 and a one year high of $27.45. The firm has a 50-day simple moving average of $8.37.
Several equities research analysts recently weighed in on the stock. Evercore ISI assumed coverage on shares of Myovant Sciences in a research report on Thursday, April 11th. They set an “outperform” rating for the company. Citigroup began coverage on shares of Myovant Sciences in a research report on Thursday, May 30th. They set a “buy” rating and a $25.00 price objective for the company. Zacks Investment Research cut shares of Myovant Sciences from a “buy” rating to a “hold” rating in a report on Wednesday, July 31st. Finally, ValuEngine raised shares of Myovant Sciences from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Myovant Sciences presently has an average rating of “Buy” and a consensus price target of $26.83.
About Myovant Sciences
Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.
Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.